Lexicon Pharma (LXRX) Misses Q2 EPS by 2c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.01 -1.47%
Revenue Growth %: -78.9%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -78.9%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $4 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Generation Income Properties Enters Into Warrant Exercise Transaction for $4.3 Million in Gross Proceeds
- Arrive AI Partners With DXC to Extend Autonomous Delivery Into Enterprise-Scale Manufacturing
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
